2021, Number 1
An atypical case of lung neoplasia
Language: Spanish
References: 12
Page:
PDF size: 155.23 Kb.
ABSTRACT
Introduction: Lung cancer is considered the malignant tumor that produces more deaths in the world over other cancers and in 90% of cases they are diagnosed in advanced stages.Objectives: To describe an atypical form of presentation of lung neoplasia.
Clinical case: A 68-year-old male patient, a smoker over 37 years of age, with a history of heart failure for which he was treated with nitrosorbide (10 mg) 1 tablet every 8 hours and aspirin (125 mg) 1 tablet per day. He reported pain in the lower left limb, which was not relieved throughout the day and was exacerbated by physical movements and efforts. In addition, there was an increase in volume in the middle anterior region of the chest, approximately 15 cm long, hard, painful, with regular edges, smooth surface. He had no cough, dyspnea, fever or other symptoms.
Conclusions: The patient had a different form of lung neoplasia presentation. He did not present respiratory manifestations that oriented towards the identification of a pulmonary cause. The identification of the carcinogenic pattern is necessary, as well as its staging to prescribe the appropriate treatment and management.
REFERENCES
Zimmermann ML, Bahurin A, Innos K. Tendencias divergentes en la incidencia de cáncer de pulmón por género,edad y tipo histológico en Estonia: un estudio nacional basado en la población. BMC Cáncer. 2017 [acceso: 10/11/2018]; 17(1): [aprox. 20 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577806
Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. Epidemiología internacional del cáncer de pulmón: últimas tendencias, disparidades y características tumorales. J Thorac Oncol. 2016 [acceso: 4/10/2018]; 11(10): [aprox. 30 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512876
Cáceres Lavernia HH, Nenínger Vinageras E. Comportamiento del cáncer de pulmón células pequeñas en el hospital Hermanos Ameijeiras. Revista Electrónica Dr. Zoilo E. Marinello Vidaurreta. 2016 [acceso 7/12/2018]; 41(2): [aprox. 12 p.]. Disponible en: http://revzoilomarinello.sld.cu/index.php/zmv/article/view/630/html_146
Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, et al. Un estudio aleatorizado de fase II de Linsitinib (OSI-906) frente a Topotecán en pacientes con cáncer de pulmón de células pequeñas recurrente. Oncologist. 2016 [acceso 5/9/2018]; 21(10): [aprox. 7 p.]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061534/pdf/theoncologist_16220CTR.pdf
Acosta Reynoso IM, Remón Rodríguez L, Segura Peña R, Ramírez Ramírez G, Carralero Rivas Á. Factores de riesgo en el cáncer de pulmón. CCM. 2016 [acceso 3/1/2019]; 20(1): [aprox. 10 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1560-43812016000100005&lng=es&nrm=iso&tlng=es
Pérez Guerra LE, Rodríguez Flores O, Morales Morales Y, Amores Ramos A, Jaime Valdés L, Pérez Rodríguez A. Cáncer de pulmón: aspectos clínicos y diagnósticos en pacientes afectados del Policlínico “Marta Abreu”. Estudio de cinco años. Acta méd centro. 2017 [acceso 7/12/19]; 11(3):[aprox. 8 p.]. Disponible en: http://www.revactamedicacentro.sld.cu/index.php/amc/article/view/833/1036
Barbosa IR, Bernal Pérez MM, Costa ICC, Jerez-Roig J, de Souza DLB. Supervivencia del cáncer de pulmón en pacientes tratados en un hospital de referencia en Zaragoza (España). Semergen. 2016 [acceso 12/12/2018];42(6):380-87. Disponible en: https://www.clinicalkey.es/#!/content/journal/1-s2.0-S113835931500266X